6.3.1.6.9.4 Calcium Channel Blockers Class IIa
APPENDIX 3. ABBREVIATIONS
AAFP = American Academy of Family
Physicians
ACC = American College of Cardiology
ACE = angiotensin converting enzyme
ACEP = American College of Emergency
Physicians
ACLS = advanced cardiac life support
AED = automated external defibrillator
AF = atrial fibrillation
AFFIRM = Atrial Fibrillation Follow-up
Investigation of Rhythm Management
AHA = American Heart Association
ALS = advanced life support
AMI = acute myocardial infarction
AMI-SK = Acute Myocardial Infarction-
Streptokinase
ARB = angiotensin receptor blocker
ARD = absolute risk difference
ASSENT = Assessment of the Safety and
Efficacy of a New Thrombolytic Regimen
ATP III = Adult Treatment Panel III report
AV = atrioventricular
AVID = Antiarrhythmics Versus Implantable
Defibrillators
bpm = beats per minute
CABG = coronary artery bypass graft surgery
CAPRICORN = Carvedilol Post-infarct Survival
Controlled Evaluation
CAPRIE = Clopidogrel vs. Aspirin in Patients at
Risk of Ischemic Events
CAPTIM = Comparison of Primary Angioplasty
and Prehospital Thrombolysis in the Acute Phase of Myocardial
Infarction
CARE = Cholesterol And Recurrent Events
CCP = Cooperative Cardiovascular Project
CCS = Canadian Cardiovascular Society
CCU = coronary care unit
CHD = coronary heart disease
CHF = congestive heart failure
CI = confidence interval
CK = creatine kinase
C-PORT = Cardiovascular Patient Outcomes
Research Team
CPR = cardiopulmonary resuscitation
CT = computed tomography
CURE = Clopidogrel in Unstable angina to
prevent Recurrent Events
DANAMI = DANish multicenter Trial in Acute
Myocardial Infarction
DRS = Diltiazem Reinfarction Study
DVT = deep venous thrombosis
ECG = electrocardiogram
ECMO = extracorporeal membrane
oxygenation
by guest on April 2, 2018
http://circ.ahajournals.org/
NHLBI = National Heart, Lung, and Blood Institute
NRMI = National Registry of Myocardial
Infarction
NS = not significant
NSTEMI = non–ST-elevation myocardial
infarction
OR = odds ratio
PCI = percutaneous coronary intervention
PCWP = pulmonary capillary wedge pressure
PH = parenchymal hemorrhage
PRAGUE = PRimary Angioplasty in patients
transferred from General community hospitals to specialized PTCA Units with or without Emergency throm- bolysis
Primary
care provider = physician, nurse practitioner, physi-
cian assistant
RBBB = right bundle-branch block
REACT = Rapid Early Action for Coronary
Treatment
RR = relative risk
RRR = relative risk reduction
RV = right ventricular, right ventricle
SAVE = Survival and Ventricular Enlargement
SCD = sudden cardiac death
SHOCK = SHould we emergently revascularize
Occluded Coronaries for cardiogenic shocK?
SPECT = single-photon emission computed
tomography
STEMI = ST-elevation myocardial infarction
TEE = transesophageal echocardiography
TIA = transient ischemic attack
TIMI = thrombolysis in myocardial infarction
TIMI 0 = TIMI grade 0 flow, or no perfusion
TIMI 1 = TIMI grade 1 flow, or penetration
without perfusion
TIMI 2 = TIMI grade 2 flow, or partial perfu-
sion
TIMI 3 = TIMI grade 3 flow, or complete per-
fusion
TLC = Therapeutic Lifestyle Changes
tPA = tissue plasminogen activator
TRACE = Trandolapril Cardiac Evaluation
UA = unstable angina
UFH = unfractionated heparin
VALIANT = Valsartan in Acute Myocardial
Infarction Trial
VF = ventricular fibrillation
VSR = ventricular septal rupture
VT = ventricular tachycardia
WARIS = Warfarin-Aspirin Reinfarction Study
WHI = Women’s Health Initiative
by guest on April 2, 2018
http://circ.ahajournals.org/
17. Rosenberg RD, Aird WC. Vascular-bed: specific hemostasis and
hypercoagulable states. N Engl J Med 1999;340:1555-64.
18. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave- front phenomenon of ischemic cell death: 1. Myocardial infarct
size vs duration of coronary occlusion in dogs. Circulation
1977;56:786-94.
19. Hasche ET, Fernandes C, Freedman SB, Jeremy RW. Relation between ischemia time, infarct size, and left ventricular function
in humans. Circulation 1995;92:710-9.
20. DeWood MA, Spores J, Notske R, et al. Prevalence of total coro- nary occlusion during the early hours of transmural myocardial
infarction. N Engl J Med 1980;303:897-902.
21. de Feyter PJ, van den Brand M, Serruys PW, Wijns W. Early angiography after myocardial infarction: what have we learned?
Am Heart J1985;109:194-9.
22. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arterio-
graphic findings soon after non–Q-wave myocardial infarction. N
Engl J Med1986;315:417-23.
23. Early effects of tissue-type plasminogen activator added to con- ventional therapy on the culprit coronary lesion in patients pre- senting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) trial.
Circulation 1993;87:38-52.
24. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J,
Simoons ML. Acute myocardial infarction. Lancet 2003;361:847-
58.
25. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial
infarction. N Engl J Med 1993;329:673-82.
26. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase
with alteplase for acute myocardial infarction. N Engl J Med
1997;337:1118-23.
27. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute
myocardial infarction. N Engl J Med 1997;337:1124-30.
28. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind ran- domised trial. Assessment of the Safety and Efficacy of a New
Thrombolytic Investigators. Lancet 1999;354:716-22.
29. Intravenous NPA for the Treatment of Infarcting Myocardium Early; InTIME-II, a double-blind comparison of single-bolus lan- oteplase vs accelerated alteplase for the treatment of patients with
acute myocardial infarction. Eur Heart J 2000;21:2005-13.
30. Topol EJ, for the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or com- bination reduced fibrinolytic therapy and platelet glycoprotein
IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;
357:1905-14.
31. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute
myocardial infarction. Lancet 2001;358:605-13.
32. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents
in acute myocardial infarction. Circulation 1998;98:2695-701.
33. White H, for the Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic
REFERENCES
1. Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the early management of patients with acute myocardial infarc- tion: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with
Acute Myocardial Infarction) J Am Coll Cardiol 1990;16:249-92.
2. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on
Management of Acute Myocardial Infarction). J Am Coll Cardiol
1996;28:1328-428.
3. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines
(Committee on Management of Acute Myocardial Infarction). J
Am Coll Cardiol1999;34:890-911.
4. Braunwald E, Antman E, Beasley J, et al. ACC/AHA 2002 guide- line update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee
on the Management of Patients With Unstable Angina). J Am Coll
Cardiol 2002;40:1366.
5. Mehta RH, Montoye CK, Gallogly M, et al, for the GAP Steering Committee of the American College of Cardiology. Improving quality of care for acute myocardial infarction: the Guidelines
Applied in Practice (GAP) initiative. JAMA2002;287:1269-76.
6. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to medicare beneficiaries, 1998-1999 to 2000-2001.
JAMA2003;289:305-12.
7. Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in
the quality of care for enrollees in medicare managed care. JAMA
2002;287:1288-94.
8. Libby P. Current concepts of the pathogenesis of the acute coro-
nary syndromes. Circulation2001;104:365-72.
9. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome
without ST elevation: implementation of new guidelines. Lancet
2001;358:1533-8.
10. Davies MJ. The pathophysiology of acute coronary syndromes.
Heart 2000;83:361-6.
11. Falk E. Plaque rupture with severe pre-existing stenosis precipi- tating coronary thrombosis: characteristics of coronary athero-
sclerotic plaques underlying fatal occlusive thrombi. Br Heart J
1983;50:127-34.
12. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarc- tion in patients with mild-to-moderate coronary artery disease?
Circulation 1988;78:1157-66.
13. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its
role in atherosclerosis. JAMA1999;282:2035-42.
14. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a chronic systemic cause of instability of atheroscle-
rotic plaques. Lancet 2000;355:19-24.
15. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.
Circulation2002;105:1135-43.
16. Dahlbäck B. Blood coagulation. Lancet2000;355:1627-32.
by guest on April 2, 2018
http://circ.ahajournals.org/
2054-9.
48. Goldberg RJ, Yarzebski J, Lessard D, Gore JM. A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a
community-wide perspective. J Am Coll Cardiol 1999;33:1533-9.
49. Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990s: their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction
(CAMI) Study. J Am Coll Cardiol 1996;27:1119-27.
50. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). JAMA2001;285:2486-97.
51. National Kidney Foundation practice guidelines for chronic kid-
ney disease: evaluation, classification, and stratification. Ann
Intern Med 2003;139:137-47.
52. National Heart, Lung, and Blood Institute. Act in Time to Heart Attack. Available at http://www.nhlbi.nih.gov/actintime, 2003. Accessed May 15, 2003.
53. Wenger NK. You’ve come a long way, baby: cardiovascular health and disease in women: problems and prospects.
Circulation2004;109:558-60.
54. American College of Cardiology. Guidelines Applied in Practice. Available at http://www.acc.org/gap/gap.htm, 2003. Accessed May 15, 2003.
55. American Heart Association. Get With the Guidelines. Available at http://www.americanheart.org/presenter.jhtml?identifier=1165, 2003. Accessed May 15, 2003.
56. Topol EJ, Kereiakes DJ. Regionalization of care for acute
ischemic heart disease: a call for specialized centers. Circulation
2003;107:1463-6.
57. Califf RM, Faxon DP. Need for centers to care for patients with
acute coronary syndromes. Circulation 2003;107:1467-70.
58. Willerson JT. Editor’s commentary: centers of excellence.
Circulation 2003;107:1471-2.
59. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Pub. No. 02-5125. Bethesda, MD: National Heart, Lung, and Blood Institute, 2002;284 pages. Guidelines, Related Tools, and Patient Information available at http://www.nhlbi.nih.gov/guide- lines/cholesterol/index.htm. Accessed May 15, 2003.
60. Wielgosz AT. What do we really know about secondary preven-
tion after myocardial infarction? Can J Cardiol 1995;11(Suppl
A):31A-32A.
61. Ebrahim S, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2000CD001561.
62. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin
treatment trials: a meta-analysis. Arch Intern Med 1999;159:
1793-802.
63. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College
of Cardiology. Circulation1999;100:1481-92.
64. Risk Assessment. American Heart Association. Available at: http://www.americanheart.org/presenter.jhtml?identifi- er=3003499, 2004. Accessed May 15, 2003.
65. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for pri- mary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction therapy for acute myocardial infarction: the HERO-2 randomised
trial. Lancet 2001;358:1855-63.
34. Brener SJ, Barr LA, Burchenal JE, et al, for the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute
myocardial infarction. Circulation 1998;98:734-41.
35. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angio- graphic restenosis rate after the placement of coronary stents fol-
lowing acute myocardial infarction. J Am Coll Cardiol
2000;35:915-21.
36. Montalescot G, Barragan P, Wittenberg O, et al, for the Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up (ADMIRAL) Investigators. Platelet glycoprotein IIb/IIIa inhibition with coro-
nary stenting for acute myocardial infarction. N Engl J Med
2001;344:1895-903.
37. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angio- plasty for acute myocardial infarction: a meta-analysis of ran-
domized clinical trials. Am J Cardiol 2001;88:297-301.
38. Stone GW, Grines CL, Cox DA, et al, for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute
myocardial infarction. N Engl J Med 2002;346:957-66.
39. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data.
Lancet 2002;359:294-302.
40. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction:
a quantitative review of 23 randomised trials. Lancet 2003;
361:13-20.
41. Braunwald E, Pfeffer MA. Ventricular enlargement and remodel- ing following acute myocardial infarction: mechanisms and man-
agement. Am J Cardiol 1991;68:1D-6D.
42. Pfeffer MA. Left ventricular remodeling after acute myocardial
infarction. Annu Rev Med1995;46:455-66.
43. Weisman HF, Healy B. Myocardial infarct expansion, infarct
extension, and reinfarction: pathophysiologic concepts. Prog
Cardiovasc Dis 1987;30:73-110.
44. Weber KT. Aldosterone in congestive heart failure. N Engl J Med
2001;345:1689-97.
45. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of
Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:
2056-63.
46. American Heart Association. Heart Disease and Stroke Statistics — 2004 Update. Dallas, TX: American Heart Association; 2003. Available at http://www.americanheart.org/presenter.jhtml?iden- tifier=3000090. Accessed November 15, 2003.
46a. Wiviott SD, Morrow DA, Giugliano RP, et al. Performance of the thrombolysis in myocardial infarction risk index for early acute coronary syndrome in the National Registry of Myocardial Infarction: a simple risk index predicts mortality in both ST and
non-ST elevation myocardial infarction. J Am Coll Cardiol
2003;41:365A.
47. Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D. Temporal trends in event rates after Q-wave myocardial
infarction: the Framingham Heart Study. Circulation 1999;100:
by guest on April 2, 2018
http://circ.ahajournals.org/
108:1682-7.
79. Hung J. Medical Issues Committee of the National Heart Foundation of Australia. Aspirin for cardiovascular disease pre-
vention. Med J Aust2003;179:147-52.
80. Dracup K, Alonzo AA, Atkins JM, et al. The physician’s role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program (Working Group on Educational Strategies to Prevent Prehospital Delay in Patients at High Risk for Acute
Myocardial Infarction). Ann Intern Med 1997;126:645-51.
81. Hedges JR, Feldman HA, Bittner V, et al, for the REACT Study Group. Impact of community intervention to reduce patient delay time on use of reperfusion therapy for acute myocardial infarc- tion: Rapid Early Action for Coronary Treatment (REACT) trial.
Acad Emerg Med 2000;7:862-72.
82. Canto JG, Zalenski RJ, Ornato JP, et al, for the National Registry of Myocardial Infarction 2 Investigators. Use of emergency med- ical services in acute myocardial infarction and subsequent qual- ity of care: observations from the National Registry of
Myocardial Infarction 2. Circulation 2002;106:3018-23.
83. Goldberg R, Goff D, Cooper L, et al. Age and sex differences in presentation of symptoms among patients with acute coronary disease: the REACT Trial. Rapid Early Action for Coronary
Treatment. Coron Artery Dis 2000;11:399-407.
84. Hutchings CB, Mann NC, Daya M, et al. Rapid Early Action for Coronary Treatment Study. Patients with chest pain calling 9-1-1 or self-transporting to reach definitive care: which mode is quick- er? Am Heart J 2004;147:35-41.
85. Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest
during self-transport for chest pain. Ann Emerg Med 1996;28:
612-6.
86. Brown AL, Mann NC, Daya M, et al. Demographic, belief, and situational factors influencing the decision to utilize emergency medical services among chest pain patients: Rapid Early Action
for Coronary Treatment (REACT) study. Circulation 2000;102:
173-8.
87. Goff DC, Feldman HA, McGovern PG, et al, for the Rapid Early Action for Coronary Treatment (REACT) Study Group. Prehospital delay in patients hospitalized with heart attack symp-
toms in the United States: the REACT trial. Am Heart J1999;138:
1046-57.
88. Herlitz J, Karlson BW, Liljeqvist JA, Strömbom U, Holmberg S. Early identification of acute myocardial infarction and prognosis
in relation to mode of transport to hospital. Am J Emerg Med
1992;10:406-12.
89. Ho MT, Eisenberg MS, Litwin PE, Schaeffer SM, Damon SK. Delay between onset of chest pain and seeking medical care: the
effect of public education. Ann Emerg Med1989;18:727-31.
90. Dracup K, Moser DK, Eisenberg M, Meischke H, Alonzo AA, Braslow A. Causes of delay in seeking treatment for heart attack
symptoms. Soc Sci Med1995;40:379-92.
91. Herlitz J, Blohm M, Hartford M, et al. Follow-up of a 1-year media campaign on delay times and ambulance use in suspected
acute myocardial infarction. Eur Heart J 1992;13:171-7.
92. Luepker RV, Raczynski JM, Osganian S, et al. Effect of a com- munity intervention on patient delay and emergency medical service use in acute coronary heart disease: the Rapid Early
Action for Coronary Treatment (REACT) Trial. JAMA
2000;284:60-7.
93. Wright RS, Kopecky SL, Timm M, et al, for the Wabasha Heart Attack Team. Impact of community-based education on health care evaluation in patients with acute chest pain syndromes: the for adult patients without coronary or other atherosclerotic vascu-
lar diseases. American Heart Association Science Advisory and
Coordinating Committee. Circulation2002;106:388-91.
66. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking ces- sation on mortality after myocardial infarction: meta-analysis of
cohort studies. Arch Intern Med 2000;160:939-44.
67. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta
regression analysis. BMJ 1999;318:1730-7.
68. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC scientific state- ment: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of
Cardiology. Circulation 2001;104:1577-9.
69. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guide-
lines for cardiovascular disease prevention in women. Circulation
2004;109:672-93.
70. Treating tobacco use and dependence: a clinical practice guide- line. Office of the Surgeon General. Available at http://www.sur- geongeneral.gov/tobacco, 2000. Accessed May 15, 2003. 71. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002
guideline update for the management of patients with chronic sta- ble angina: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). Available at www.acc.org/clinical/guidelines/stable/stable.pdf, 2002. Acces- sed December 2, 2003.
72. Chobanian AV, Bakris GL, Black HR, et al, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National